|
1.
|
|
12 p, 1.3 MB |
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis : a real-world multicenter experience from Spain
/
Valero-Martínez, Cristina (Hospital Universitario de La Princesa) ;
Urgelles, Judit Font (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sallés, Meritxell (Althaia Xarxa Assistencial Universitària) ;
Joven-Ibáñez, Beatriz E. (Hospital 12 de Octubre (Madrid)) ;
de Juanes, Alexia (Hospital 12 de Octubre (Madrid)) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Laiz, Ana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Moreno Martínez-Losa, Mireia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pujol, Manel (Hospital Universitari MútuaTerrassa) ;
Beltran Catalan, Emma (Hospital del Mar (Barcelona, Catalunya)) ;
Pinto-Tasende, José Antonio (Hospital Universitario de A Coruña) ;
Crespí, Laura (Hospital de Manacor) ;
Sala-Icardo, Luis (Hospital de Torrejón de Ardoz) ;
Castañeda, Santos (Universidad Autónoma de Madrid) ;
García-Vicuña, Rosario (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. [...]
2023 -  10.3389/fimmu.2023.1283251
Frontiers in immunology, Vol. 14 (october 2023)
|
|
|
2.
|
|
29 p, 401.7 KB |
Epigenetic targets in B- and T-cell lymphomas : latest developments
/
Ribeiro, Marcelo L. (Sao Francisco University Medical School) ;
Sánchez Vinces, Salvador (Sao Francisco University Medical School) ;
Mondragón, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Non-Hodgkin's lymphomas (NHLs) comprise a diverse group of diseases, either of mature B-cell or of T-cell derivation, characterized by heterogeneous molecular features and clinical manifestations. While most of the patients are responsive to standard chemotherapy, immunotherapy, radiation and/or stem cell transplantation, relapsed and/or refractory cases still have a dismal outcome. [...]
2023 - 10.1177/20406207231173485
Therapeutic Advances in Hematology, Vol. 14 (1-12 2023)
|
|
|
3.
|
|
11 p, 474.2 KB |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
/
Socinski, Mark A. (Univeristy of Pittsburgh Cancer Institute) ;
Kaye, Frederic J. (University of Florida College of Medicine) ;
Spigel, David R. (Sarah Cannon Research Institute) ;
Kudrik, Fred J. (South Carolina Oncology Associates) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Ellis, Peter M. (Juravinski Cancer Centre) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Lorigan, Paul (University of Manchester/Christie NHS Foundation Trust) ;
Gandhi, Leena (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Gutierrez, Martin E. (Holy Cross Hospital) ;
Nepert, Dale (Clinical Development. ImmunoGen Inc) ;
Corral, Jesus (Hospital 12 de Octubre (Madrid)) ;
Ares, Luis Paz (Hospital 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide chemotherapy in patients with extensive-disease small-cell lung cancer. [...]
2017 - 10.1016/j.cllc.2016.09.002
Clinical Lung Cancer, Vol. 18 Núm. 1 (january 2017) , p. 68-76.e2
|
|
|
4.
|
|
|
5.
|
|
15 p, 2.0 MB |
Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event : the international VULCANO randomised clinical trial
/
Mostaza, José M. (Hospital Carlos III (Madrid)) ;
Suárez-Fernández, Carmen (Universidad Autónoma de Madrid) ;
Cosín-Sales, Juan (Universidad UCH-CEU) ;
Gomez Huelgas, Ricardo (Universidad de Málaga) ;
Brotons, Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Araujo, Francisco Pestana (Hospital dos Lusíadas) ;
Borrayo, Gabriela (Instituto Mexicano del Seguro Social (IMSS)) ;
Ruiz, Emilio (Ferrer Internacional) ;
Universitat Autònoma de Barcelona
Cardiovascular (CV) polypills are a useful baseline treatment to prevent CV diseases by combining different drug classes in a single pill to simultaneously target more than one risk factor. The aim of the present trial was to determine whether the treatment with the CNIC-polypill was at least non-inferior to usual care in terms of low-density lipoprotein cholesterol (LDL-c) and systolic BP (SBP) values in subjects at high or very high risk without a previous CV event. [...]
2022 - 10.1186/s12872-022-03013-w
BMC Cardiovascular disorders, Vol. 22 (december 2022)
|
|
|
6.
|
|
13 p, 2.5 MB |
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
/
Ribeiro, Marcelo Lima (Sao Francisco University Medical School. Laboratory of Immunopharmacology and Molecular Biology) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Blecua, Pedro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Reyes Garau, Diana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Miskin, Hari P. (TG Therapeutics (New York)) ;
Bosch José, Francesc Xavier 1947- (Vall d'Hebron Institut d'Oncologia) ;
Esteller, M. (Institució Catalana de Recerca i Estudis Avançats) ;
Normant, Emmanuel (TG Therapeutics (New York)) ;
Roué, Gaël (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory (R/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody. [...]
2023 - 10.3389/fimmu.2023.1130052
Frontiers in immunology, Vol. 14 (April 2023) , art. 1130052
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
19 p, 633.5 KB |
Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
/
Miravitlles, M. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Auladell-Rispau, Ariadna (Institut d'Investigació Biomèdica Sant Pau) ;
Monteagudo, M. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vázquez-Niebla, Juan Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Mohammed, J. (Dept of Physiotherapy. Bayero University) ;
Núñez, Alexa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Urrútia, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD; however, a significant proportion of patients at low risk of exacerbations are treated with ICSs. We conducted a systematic review including a diversity of types of study designs and safety outcomes with the objective of describing the risk of adverse effects associated with the long-term use of ICSs in patients with COPD. [...]
2021 - 10.1183/16000617.0075-2021
European Respiratory Review, Vol. 30 Núm. 160 (june 2021) , p. 210075
|
|
|
10.
|
|
5 p, 522.5 KB |
Novel combination coccospheres from Helicosphaera spp indicate complex relationships between species
/
Sturm, Daniela (The Marine Biological Association of the United Kingdom) ;
Langer, Gerald (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals) ;
Wheeler, Glen (The Marine Biological Association of the United Kingdom)
Coccolithophores play an important role in global biogeochemical cycling, but many aspects of their ecology remain poorly understood, including their heteromorphic haplo-diplontic life cycle. The presence of combination coccospheres in environmental samples, which represent a transition between the lightly calcified haploid (HOL) and heavily calcified diploid (HET) life phases, provides crucial evidence linking the two life cycle phases of a particular species. [...]
2022 - 10.1093/plankt/fbac044
Journal of Plankton Research, Vol. 44, Issue 6 (November 2022) , p. 838
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
